Neuronetics' NeuroStar Depression Therapy Not Backed By Data - Blues
This article was originally published in The Gray Sheet
Executive Summary
Existing evidence does not support the long-term efficacy of Neuronetics' NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression, according to a recent 1assessment by the Blue Cross and Blue Shield Association Technology Evaluation Center
You may also be interested in...
Neuronetics Plans Expanded Marketing For Transcranial Magnetic Stimulation Depression Therapy
Despite a recent negative Blue Cross Blue Shield technology assessment, Neuronetics is moving ahead with plans to expand sales and marketing efforts for its NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression.
Neuronetics Plans Expanded Marketing For Transcranial Magnetic Stimulation Depression Therapy
Despite a recent negative Blue Cross Blue Shield technology assessment, Neuronetics is moving ahead with plans to expand sales and marketing efforts for its NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression.
FDA Neuro Devices Panel Examines Suicide Risk In Depression Trial Subjects
Clinical trials of devices for depression do not readily lend themselves to hard-and-fast rules on when the rate of patient suicides might require a trial to be halted, according to FDA’s neurological devices panel.